TQC2731
Phase 3Small molecule
TQC2731 is one of 102 small molecule programs targeting Sinusitis. It is currently in Phase 3.
4
Indications
6
Total Trials
3
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1TQC2731
SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Cinqair
TevaPreclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Arcoxia
NovartisPreclinical
Atrovent
Boehringer IngelheimPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Allergen Immunotherapy Extract
JJohns Hopkins University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma2 trials
Chronic Obstructive Pulmonary Disease1 trial
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Active, not recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT06707883·258 enrolled
Sinusitis1 trial
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07107256·246 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQC2731. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details